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Oral cl-phalosponn.\ h~ve been u~d pnm.:uil tor the trcaOllCIlt of
colTlIJIunity-a '(Iuired infectio~ mch as omJnunity-acquirt'(!
pneumonia. pharynglOs. otim mcdia. bronchiti.. ~kin. ami ~k.i11
muuure IIlfc:cnons :lnd uncomphc.lted unn:uy traU II1fcctl 115. The
go:tl m the ckvcloprnent of the fir.;t or.u cephaJosp0nJl5 w to
Improve theIr ph~mlaCokmetlc profile. HaVIng a cOlllpli~hed that,
rJle n('xt \ (0 cnh.,'mce meir antibauerial actiVIty. The newer oral
cephal rorim dClllonstr.ltc ~n IOcrC:lS<."<l ill I ilro ~nnbaucrial acti\~IY
:md cnh.lnced I3-beramasc sr.lbility ~nd phanmeoj..,'inetie properties
able I). TIll')' not only provide an altemanvc for me trC3tment of
mfecoons It1 rJ1C community due to p~thogens rCSlSt':U1t to other
annnllcrobial agents. bUl mor improved phamlacokinen meR";I.~e
COlllpltancC. [n addinol1 rJ1CY m.l)' be l~ • 1111 dIe hospllal ~-rcing lor
swltchlll~ from parentt:ra! [() ()ra! mt:r:lpy. thereby decreasing osc
and .illO\Vlng L-:Jrllt:.r panent dtschargc. The new ra! ceph:lI0sp0mc>
Clln be dWJ(led Into tho'\<: ~bsorbed as rJle parent compound
(ce mmr. ccliibuten. cdiXlJ11e and cefjJmw) and those ~bsorbed in
IllC (111) of ester prodru~ (ccfUroxime axenl, Ce!pOCIOlClJllC proxenl
and cefcramel plVoxil). In thIS paper, bec3l15c of sp~cc limlclliolls,
Wt: \VlII TL'View Illc roll' nf thl'SC ne\ oral ceph:J!mporins in ~
~Iecred number of impoTt;lI1t clinical indications.
PHARYNGITIS AND TONSIlliTIS
Pharyngitis due CO Slr'1J1l1/wrus JiYOI!fllCS (group A ~-helll()Jyti
\crcpmcocci [GABI-I ]) is one of the mOSt cOlllmon b~ct 'rial
·orr."pondtng ~ur.hor • nd repnm rcque<cs: I r 1 ollald E. Low.
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mfc nons ~een III gener.J1 medical pracllce. accounting fI r a
slgnificalll lIumber 0 plly 'jcian office visi pcr year. Although
patients recover dinic:tlly wimout alltibiotic therapy. treatment is
recommended 10 ha tell clil1Jeal r olution. 10 prevcnt rhclllnati
lever and to reduce the lIlodence of lo ally IIIvaslVt: in.fection.
ince irs Introduction in the 19405. peniCilli n has bCt:11 till:
'gold st.ndard· tre:ltI11<."nt tor streptococcal ph. ryngitis II]. ~nd
for many yc~~ It dfectl·d consi<tem microbiologic e dication
rates of over 90";" 12J. However. in 1I10rc recent year.;. the
mcidenee of baucnologic failure \vim oral penIcillin dlCr:Jpy h.l5
UlcrC3Sed to as Illuch as ttWtr3()'1A, [3.41· Altcmatlvely I3-lactrulla.~c­
<;tablc oral c<.'phalosporins have bcC'n Jl<l\Vl1 to bc highly effecnve
In mt: trcatl11ent ofstn:ptocoe I phal)'ngius [3,-11. In addition. trial<
ofCXI anded-and bro~d-~ctrurn oral cephalosp rin. in Europe [51
~nd llIore rcccmly III Nonh Americ~ (6) su!;b>est th.,t ~ 5- to 7-day
duration ofthcrapy is .1S effcctive ~.< or even more cHi: rive dIan the
cbssi .1 lO-<by re~men of pcl1lcilJin.
The phenomenon of lugller /'yo!lclles er:ldlcation . tes for
ccph~losporill\ ha~ been prevIously noted. Pichichero and
Marg li.~ have reviewcd a number of studies comparing
cephalosporin with pelllcillin for the tre~nnent ofstreptowccal
pharyngJos PI. Bascd on thclr meta-analysis. they concluded
Ihat the ccphalosponns arc gcneraHy more efficaCiOUS.
presumably due to their rcsistance to degradatIon by p-
lactamasc. This Ill. y be espc ially tnle for pancnt5 wuh
recurrent crcpto 0 cal ph. ryngitis who h;1VC been treated
with pemcillm within the prt:violl 3 montl [RI. his opinion
is l10r h~rcd universally, however. h1.l1lllan an I colleague
have ilio reVle\ cd the llIdics included in the Plchichem
mcta-analySlS, and con luded th~t tht: available literature docs
not sho\ tbat ccph~[osponm 'Ire Sllpenor 10 penicillin for
Table 1 Pharmacokin lies 01 oral eepholosporins aher songle dose on heallhv volumeers
Antimicrobial Dose (mg) Frequency C,"•• (mg/l) AUCQ., (mg hIll 1./2 (h) Urln ry elimination (%)
Celix,me 400 00 3.6 26 3.1
CeluroX'nlll'8XUlIl 600 BID 4.9 19 2 32
Cehibul n 400 00 17 79 2.3
Cerpodoxlme-proxlllll 400 00 45 27 2.4 24
Calp,021' 600 BID 10 30 13 70
Celetamet·plvoxil 600 BID 41 25 2.3 22
CefdlOlr 300 BID 1.6 6.6 1.4 18
Adapled Irom (17).
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Ir,atm,lll of 'trqHo 0("(;11 pharyll¢m 1'1). The foood and
Dn,~ Adlllllll>tr.mon in lhe U~A h:,s .,pproved rhe u e of.1
'i-,by couI'e of cefJll1lr (or the treatll1ent of strepwcm:c:11
pharyn~lI\ .1I1d had previously approved cetpodoxune
prnxenl Ic)( 'i-day ther;lpy J\ \\'ell. All of the newer oral
cephalo'porlll. h.I\'I' eXlclkm aCllv,ry a!-:,lIn\1 the ;AHH'
wllh MIC", < 1 111~/L.
OTITIS MEDIA
Acute otitiS l11edlJ COllrlllllC' to b, an 1Il1port.lIlt pubhc health
I'rohlelll ,lroul1d lhe \\'orld, TIll' 111051 (onl1nOI1 bal"lel'l,1
1'.1lhogl'n, ,';'"'/'/('("((1/ 11111:11111 1111r'",', h,,, hel'n Il1lphc.1lnl .1' p:1I'l
of the cl1I'rellt antibIOtic r("l\lanCe cnsi\, The tiN c,l\e\ of
pelll 11I1ll-rl'~lst,11It • '. l",rll'//C>II"'1' were repol1ed III A,lstrali:1
al1d New GUlIlea IJI the early l'nOI. r11 k·ss Ihan a ,it'cad"
Ill~hly re\I\lant ,tr.lil1\ that 'XllIhltl'd resistall e rn Illultlple
,llltlbl(~{1 .\ werl' IsoLlt,'J Irolll pal1ell(s wllh lI1V:l.SIVl' II1fl'ctions,
al \\,,11 .1\ (rol11 orncT', in oUlh Afn a, Tht' prl'valence of
1'1:IIICillll1-r,IlItam pnt'\llIlococcal infe:ctiom has ,sc,I.'ted
\tealhly Thc Illcrt'a~lI1~ usc o( ,by-Llrt' I~Clhtit'\ pl'OVldCl a
vector tor tranSlmSSlon of reSl\tanl pnellillUCCKCI lilli,
Iml'rJlatlol1,ll 'pre:,,1 o( n:\lltal1t lsobles has been docul1lellted
111-131, '0 Ihat p ... mcllllll-r,SISt.llll plleumococcal IIlf"cnolLS
h,we be III" ,I f:lllb,l 1'1'0bJclll 11-+,151·
The (ll'tinl.ll m.1I1,I~elllent of . elite orim media is widely
d<:h~led fClr IInny rt'asOIl. 116], bq,'1ll1lillg ,It Ihe 1110,1 b:lS1'
le\'l'1 of l11elheaJ lIlanagement, hccau" there i~ no COlllellSUS
re!:o':1rdlllg Iha~1I0SlJC cntel'la, lie SeketlOIl of al1lJbl(\OC
llia,lp)' 1\ 1I\II,ll1y 1'1 II pm , heCJII\l' "fthe lhtliClilty of oblall1l11g
cultures, Ah:hollgli alllhonuel \ISl1, II)' ,I!!:ree that S. I'm'IUI">III'/{'
:lI1d IIl1rypeabk 1-I",.",01,1IiI1l5 ;,!/IIII'"zlII' al'l.' the IIlmt '0111111011
bactenal pathogen" the pTn'alence '''If r"Si~IJIICl' is litH al \\'el1
doc\1l111'med. With the excepuon of cct'tlhutell, whIch" I 'ss
active ag,llllsl lI1M,'XI'II" (malT/wlr', and S. P"t',,,,,,,//r'a(', Ihe lIew
oral c<:phal )lpOrlll. are gencr.1l1y 1Il0rl' potent IIlhlbltors of
COllllllulllty-,IClllllred r"'l'lr.1wry pathoge'" tll.IlI Ihe older I r,lI
cel'halOlporin' 1171.
Er,ldil'all011 of p.llhngell from middle car fllli I ;)11.1
chlllol omcollw ha\'l' bcen repnrted trl Ill' ks\ 1:1\Ior,lhle If
patho~en\ with redllcl,d antlllll 'robi:lI Slhll'ptlhility ~re
prescll! [I HI, Jacohs l't al. 1191 CCllldUCll'd a brge, Inter-
lIatiollal 'IUd)' of 11I1:1I1t, alld children with aCUll' "ntIS
lIIedla «l Idelltlfy p.uhogell\ ,lIld susceptlbiliry patterns,
Dllnng Ihe wmtcr of 1')<)4-'6, mlddk car flllid samplel
wer, coli,' 'ted from l) 17 p,llit::nt\ wllh ,)ClIle otlns m"dia in
13ulg;ma, Ihe 'zt'ch Rl'puhlic. HUllgJry, RUlllallia, Slova-
k..), Isr:lcl, alld [hc U, A. P,lthogen, wae l'ol:llcci frolll (,2%.
of lhl' pau<:lIls, For S. 1'/1('1//",,1/'111' (.lll·y" of the pallents),
ulHypeabk H. JI!/ll/m:Il" (17%) and .\!. WI"rrl'a/i (4%), there
was igmlicanr \', mopII alllong I':co~l'lllc re~oll, (p (I,(JIlI),
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l3-bn"llla\C W:l~ pro,lu cd hy .\1 % ;lIld IOlJ% of the I~olale,
of II. lI!n""II::a,> and ,'1'/. (,/llmllll/" rcspectlvely, he
pTl'valence of resIstant " l'''f1l11h>'''/I!' was 11Ighes[ In panelltl
Ie" thall 12 mont hs 0 agc,
Several sl\Idics havl' now reported the olltcome of lreatln~
aeLlle or pL' Iltent OUlII 1111'lha due to pnc\llllOCOCCI t1ul arc
nOl1\lIsccptihle to penICillin. A is genenLly the CJ e, 01 Opil
,v.llu,1t1on of the rymp:lfll ml'mhr:me and clifllcJI condmon
ddine Ihe olltcome measures. Thlll, tht remltl arc somewhat
slIbJectlve, espeCially III nonr.1uJolll17cd, IIwestlptor-
unblllldcd qudlcs. All the studlc' IIlcludcd an IlIl1lal
rylnp, IllKelltl',IS It r clIlnlre )f nnddle car I1wd, Cefuro~,nlL'
allli celi,r )7il. Wl're It)und tel be et1ic:KiotlS in III It of thl"
chlldrt'n cv:i1u.lled III thcse IIUdlc\; cd"c!or and cdiXlfllC 1L.1\"
nm been a~ cflcnlve ,l\ loml' of these other agents, Altholl~h
only :1 ,"mil IIl1fllba of chlldrcn were Ircated III one sOldy,
Celi:> d )Xlllle did not app";lr lU he partlclIl.lrly effective de~pl!l'
havlllg reolson,lhle III \'Itro actlVlr' :l~Ifl't S. IlIIl'lImClllillc I\UlatC\
thar lVert' nOllSlllceprible to pelllcilllll 12111, Tlu, lack uf
dTl'crivent'ss 11IIghl I os,ibly be rd. It'd 10 the n:btl\·ely low
eonn'lIl'r.1t1ons achlcved III the ll11ddle car. In a \econd smdy of
eelpodOXlm,' for otitis media. t.he ourcome In ail lour hlldren
with pelllCllhn-n Ilsu>cepuhle t:r;un, (malllly Interllledlate)
WJ~ sansf;,crory 1211.
[n rh ... ITeallll,'m f IIlfeco 11\ due w '. I'''WI/IOIIIII,' \\1th th,"
I.r, I l'el'll.Ilosporins, the r:tteS of resiSl,lIKl' lor rhc fl'gion or
COlll1try mu,1 bt' mken Into :II'COUIlt, In Europe there is .)
marked va nation in the r.lll'\ of pem IIhn-Tl,"'i1 rant
1'/H'WIIIlllillc vaIY"I~ from (1'10.....'% III The etherland> and
Italy to .'0%-52% 1I\ Hung<lty ,lIId Spam I12J.
Thc lel1~th of du'rap)' or ,CIIIC rill llIedla has hl"t'll
deb:ned. K(lzyr,;k .I t't al. 1231 condllcled a llIeta-JnalYlls of
r.lndOllllZl'n controlled rnals of antlbiollC tf('allllent of aClite
Ollm llIedl,l III cllllcirell to dererJIline whether OlllCOllll"'\ wert'
,'ump, rable: III children treated with, 1l1lblOncs tor less than 7
d,l)' or 7 day.. or Ill()re, TheIr remits Illggclled rhat 5 dJy" of
~h{)rt-aetlllg ,11t1bHll!1' usc IS eIT,'cn\'C Lrt',lllllent fOT 1111 '(1111-
pliC:ltt'd a lite milis llIe,ha III chtldren, Cohen ,'I a!. 1141. in J
prmpl'nive, l'ollll'aratlVl', dOllblc-bhnd, r:lIldOllli7Cd, nHllll-
cemer tri,tl, olllpJTcd ,11110 'icillll1/clavllbnale m duct'
diVIded doses lor I() day, \\'Irh all ldellllcal 'i-da rC~1ll11'Il,
followed by a 5-day placcbo I'enod. ula\', n.lte ,malym
~howcd th.1I the III-day cOll!>e W,I~ Itatl~lIcall\' \upenOt
(H(dl'y., v... 711.H'Yo; I) = 1I,llOHl
COMMUNITY-ACQUIRED PNEUMONIA
WIll'n cOllSldel'lng the rekvJIle<: ot anrlllllcrobial rC'l\l;mce ut
the bactcn,l1 pJlho~em lhat :Ire Ihe cnolo~c Jl\en~ 01
COllllll\lnlry-acC]\llreci pl11'II111011lJ (CAP), It IS I111 portJ III m
takt' lilt 1 COil Idcr.1I11)11 \ hetha or not the ag,1ll causes a
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COllCOIllIt:lnt hactc:rt:lTlliI and tht· level 0 rcsiMance of the:
organi~1l1 to the: anrimicrobiaL Although H. i,if/l/cllzQ<' is ofren
cited as Ont: of the mOH tTl'qul'nt causes of CAP. it I
Infrequently Isolated from the blood 1251. In stl-Idies carried
out pnor to the Il1rroductlon of the H. i,!{luclJ.zOt· type b
vaccme. approXllllatdy one-thIrd 0 ne-half f the blood
culture docuJ11t'med ascs of H. irif/II<'IIz(I<' pneumollla wert'
due: to rype b [26.271. To dare in Canada. due: ro the:
\Vldc:sprl'ad U'IC f thl' type b vaccine. rhe: rate of coloniz.1tion
:lI1d invaSIve dl. e. e. such a pneulJlonia and b:'lCteremia, i
Slb'11lficaody less In aU a~e woups [28). S. pllel/l/loi/inc is clearly
the mosr Imporonr bacrenal pathogen cau Ing AI'. ApproXJ-
marcly 0% of all a.~es of AP due to pncumococci arc
h:lcrl'remlc. :lnd thereforc p renrially ble co . u e scconcbry
infccoons .It l'xtrapulmon:lry sire..
\3-l:lctam rc istance in H. i,if/llcr/zrIl' is due almost
exclusivdy to the acqUisition and exprcssion of the TEM
and ROB ~-Iact.unasc gem.'S. urrently dle rates of ~­
Iactanuse po lOve H. irif/IH>/Izne arll > 30% [191. The relcvance
of dll Increa~e an re:SlStance W the impact f the rrC:ltmenr f
AP 15 question. hie. In .,ddition, thc ne:\ oral cepll losporins
have rer311led excellent activity against tlle ~-I ccamase positive
maim with MI <;1" ~ -\ mglL (Table 2) [17].
The usc of the oral \3-lact;lOlS for the treatment of pCI1Jci.llin-
resIStant Donmemngeal mvaSlve pneumococcaJ iltlcctlon IS
controversial [29-32J. Where: clinical data re L'lcking.
pharmacokinetics and pharm codynam.ics may provide Insight
as to the cxpccrc:d efficacy of a ~-J. tam [33-35]. Animal
stJlcllCS with various penicillins and ephalosporin.~ again t
penicillin-susceptible and -resistant pncumococci have shown
that the duraoon of tilllC that CWIll Icvels arc above me M I
IS rhe key parameter in dctermining efficacy. Mortality was
virtUally 100% ifsenlm levels wen: above the MI r r ~ 20%
of thc dOSIng IIltcrval. In contra.st. whel1 the time bovc the:
MIC was ~ 4()% for penicillins .nd 2: 30% for c ph.losporins
the mortality rate WIlS < 10"A', 1341.
MIC (moll)
The gcneral conscn us is rhat 11 nmcningeal invasive
pneumococcal infections due to strains that arc intermcdi-
ately re.lsrallr ro pel1lcillin can bc trcared with penicillin or
31110xlcllhn. There IS litde clinical cvidence for their fuilure
when treating penicillin-resistant pncumo 0 ci. even highly
re istallt Stt<lIITS. Iu IS moS[ likely the result of rhe high
concentrations achll:vcd in thc erUIll and at the sire of
lllfection 133J. Alth ugh there again i litde evidence (or
clinical f.,ilures when imcrlllt:cliatcly ,lIld high.ly pcnicilhn
re i t, nr 1l0l1mcmngeal inva ivc pncumococcal infc ri ns
:lre treared with an oral cephalosporin. they should be used
with caUtlon. especi:llly for rhe treatment of highly
peni IlIin re Isranr tr:lIl1.5. There IS a umfoml incresc of
f(,ur- to 16-fold in thc Ml of thc oral cephalosporins for
those strain of pneumococci th~t are intermcdiatdy
resistant a compared with those that are sus eptible, and
anomer lWO- to cight old increase for tmillS that are highly
penicillin resistant as compared wirh those intcrmediately
reSIstant [33,36]. raig [341 derermined me time above the
MIC for eveml 01':11 ~-Iacrams (amoxicillin-clavu]anarc,
ccf.,clor. ccfuroximc, cdprozil. lorncarbef, ccfPodoximc.
cefiximc) and found that only :ulloxicillio/c:Javulanatc was
:lbove the M I for > 40% of tllC do ing interval for
penicillin-rc istant '[TJm of pncumococci. efuroximc and
ccfprozil WlltC above the MIC for 35% and 32%,
rcspectively, o( the dosing interval. bur only for susceptible
. nd intennediarely rcsist311t pneumococci.
UNCOMPLICATED SKIN AND SOFT TISSUE INFECTIONS
Cc(Julltls is one of the most important dis 'ases of skin and
oft rissu. eUulim IS a common dl~ease. which is rarely life
thrcateomg and can u ually be: 111 naged \ ithouc hospital
dmis.si n. It i mo t commonly due to ABH and
Stnl'lryloro'''' O/lrt!II. As noted previously the new oral
ccphalosporins havc unifomuy excellent activity against
Table 2 Tho In Vl/ro activity of the new oral cephalosporins
agalnsl H. Inlll/onzao
p-Iactamase negptiva J}-Iactamasa positive
60% 90% 60% 90%
Cefixlma 0.12 0.12 0.03 0.12
Cefuroxime 1 2 1 4
Cehibulen 0.06 0.06 0.06 0.06
Cafpodoxime 0.06 0.125 0.06 0125
Cefprozi! 2 16 16 16
Cefelamel 0.12 0.25 0.25 0,5
Cefdin/r 0.12 0.25 0.12 0.25
Cefaclor 4 16 4 32
Adapted from (17J.
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GAUH, W"o: 137] ~llIdlt'd thl' phanlla' Ikllll'lln llf ,,'Illl' llf
Ill<' IIO:\\' l'l'h,II'hl'onll\ (co:fpodoxilll<' I'roX,'111. «'fur .xill1l'
aXO:III. co:ti X1111 0: , l'o:tj1rozil ,lIld o:di.ihutO:II) ,1IId !"Hllld tho:
po:no:tr,llIon IlllO 1Il11.11ll1l1atory o:xlIlbto: to be I 2% of tho:
,o:rUI1I ,'OIlCO:lllrauon for celixllll<', I 13'~I,. for cettlblllcn,
I (l.!"!" It>r cdpodoXllllt'. 92% tor l'IiHoxlme and 79%, for
cdiHozl!, Thl'ro: \\';" a r"btlon,hlp berwel'n thl' serum
dillllll,ltll 11 h.llf-hl;', of Ihe\o: ,lgel1l\ Jild ell<" de~ro:e oj [llllIl'
1'0:110:tr,Il10n, tho\<' ,lgO:Tll~ wllh Illl1f,:l'r h,dr-live, p,'Ill'tr, tllIl-(
to a I:rcater 0::'>:t('111 H"wn'o:r, Ih<'fl' '\ 111. rkl'd van3btliry In
the ,ll(lVllV of rlll"O: no:\\' Jgcms to ..... ,wrfllS (T,lhl<' 3).
Ce(IXII11O:. CO:(llhlllO:Il and Cd;,'lJlllo:l "II h.wl' MIC", _ 31
IlIg/L. 1ll,lkll1f,: thO:Ill 11113 '(0:1'1.11>10: lor tho: treJtIIH:11t oj
dnclIlllO:lHl'd S. ,II/H'//5 IIlfo:cnolls,
SEXUALLY TRANSMITTED DISEASES
Thl' c'eph3JosponIL\ I13VO: m,1111Jy beel1 rt'Conlllll'ndcd ror the
Iro:.lIl11o:lH of gOllorrhl':1. TheIr ,'"luc tor tillS IJ1dic, nOll I
e\pecl.t1ly Illll'0rlollll wnh thl' ellll'rgeno:e of pO:I1KI11Ina,0:-
pI' ,hlling ,\'ris>1'1 ill .l!"I/"lTiI""'/I', ~1ll'Cnno111ycln-rl'Slll"nt
'trams, Jlld rhe o:sol.tril1g rato:, of t]1I0roqll1l1olotll'-ro:si\I,1Il('l'
PH..'WI. With the ,'X<:<', nOll oj Cl'll:HOZII. tl1l.' 1lL'\\' orJI
cel'h,t1osponns pro\'ld,' o:x -elk'ot :ICIIVlry ,lg,ll1l.St N. ,l?,'llll'-
rl"'<'<It, (TJbk -I). 'l,fliroxl1no: is 100ss aCtlvc a~almt ChlOlllll-
lOIll.lllv rO:\I'l,1nt 1\01.ItCS rh,m 3~3UI\l: su. cepcibk ones, Thes,'
,1~,'Il!S h3\'e not only prl vtJo:d an altcruanve t[(',lllll<:1lt tor
Illlill\llru~-re~I't.ll\l ~onorrho:a. hut with a (lIll' do\" rq;illlcil
they have emllH'd ('0 IIIPb,lIICl'
SWITCH THERAPY
Wit h rl1l'r, py, till' \\\'Iteh rom .1 p,Irt'I1l31 1 an oral
31l!1Inicrobl.ll ,t~ellL hJS be<:l1 ml'd sucee sfully ill th ' trl'arll1<:nt
of 111311 'cnous IllteniOIlS. ,o:vo:rJI ,(\I lio:s h, vo: found th:tt
'1f.'1'lfieant cost \3VlnF:" C.11l ho: 3c1l1cvl'd hy switch tI,crap~'.
Mort'over, It h3\ lhe furrh<:r advam,,~e<; of shon,'llIng hospital
MIC (mg/l)
Low New oral cephalospOlins n7
,Co'y "Ild ro:ducing Il1traVO:Il0U' lme-rd,Ill'{J nmo 'onlla! b.l([o:r-
cnlla, Tho: I1l'W onl ceph losponm olro: o:xcdlo:nc 3b"t'I\t' 1;"1'
\\ ach theral • bCC:1U\e of lltc!.r phartll.lcoklllo:t1c pre pettlC'
:lnd "xpandcd III VItro :lctiVIt~" esrl'nally J~':llml ;ralll-
n<:f-",t1\'l' hacn:n:l. .ernbu ell, celixilllc alld CCfCt:ll11l'( eVt'n
exllIhir .l tlVlty ,~ll!lS1 Isolate, rC,I,t:l1lt co Ccim:lXlllle . nd
ccfbzldnllO:. C", IXJIlIC 1\ a prllll,I~' :t.lldlJ: tc f r ,Witch
rhaapy. I'rdlll11 nal)' ,md,o: h,1\'" shown ,'xcl'llent chmeal
OUICOlllO:' \ lth ~wltch tlll'r.lpy co cdixlIlle alier 2-3 d ys I' r
v.InO:lY of ,enous 1Il1~,ctIon 1411]. R.1l1mez CI al. 1411 srudio:d
sWllch thenpy In \~l) p:lllcnr., WIth :l Ill'''' roe:l1Cgl'llognphlC
pulmonary 1llliltr,\cc JIllI at 10:3,1 [WO ,ytllpro!11.S (ClOugh, tCl'o:r
or Icukocyto Il) wh) ",('rto adl1llncd to h05plC:l1 and tr<"ated
\\'ah intnvt'llou\ co:fnzOX1I11C sodium (I g o:V I.' 1')' l:l It) I
Cl'i1ri3XOIlI.' ,odium (I g l'\"'~' 24 h) Pan,'nes wa,' sWl[cho:J to
oraJ cdixIl11e (400 Il1g ,'vel)' 2-1 h) .1' '0,)11 ,h !.hcy mer [he
f;')J.Iow1I1g cnto:na: (I) I,'solutlon of t;"vcr: (2) Il'lIprovemo:nr of
cough Jill! lesplrJrory dLsrrl'ss; (3) Improvement ,)1' kllkocy-
rmlS; Jlld (4) prl.'\cl1ce: of nonllal b'3,rrotnt,'snl1al tr.lct
,II" '1'U( 11. Of rho: 121J paricm.\ o:nrollo:J 5 (62"';.) had c11111 J)
Jara cvalll,'lo:d. LOllg-tt'nll lollow-up ,hawed Ilour 7-1 p, [(t'nts
(9l)')1,,) wcre curo:J; ono: I'JCll·m Icqutr,'d rO:.Idnu slOn ri,r timlll'r
IIltraVCIlOUS theTJ!, . Mean Jur:mon of ho 1'11,1.1 ~tar was -I
day\, Thts tudy Indl Jtcs th:ll s\Vllch therapy WJS elTl',·C1ve
lro:Jtlllo:l1I and r"duco:d ho'pltal COSt hy o\'er 100 IJOO.
CONCLUSION
Tho: 1l00W OT.II n'ph,t1osponns h'l\'e: 1I0t only pI' vlded ,11
altem:llive rreatl1lellt lor cnll:rglllg muludrug reslst~lI!
par.hog"11\ 111 rho: COl11ll1UIlIf '. nUl lI1g home and ho p1l3!
.00tnl1g, hut bee, IISl' of lmprovo:d phamtlCokll1cl1cs thc ' also
n1<'r<",1 0: Oll1pltal1ll' :111.1 on\'o:nio:ncc ..... Jlh on c I' tWI C
day dosing. In :ldJiti 1\ thcy have: pmvldl'd an .hcm,lri C t
pan.'llteral th,'rapy, allowlllg th ... p, ricnc r be wltchcd 10 JIl
oral Jgent thaI rc 1.111\ 111 more cost-dlccnvc thcrapy an,i
carher dis har~c.
Tablo 3 The In WIrO actlvlly 01 Ih new o,al cephalOSPollns
agllinsl 5 numus
11.loctamase positive IHlIctamase negative
50% 90% 60% 90%
Ceflxlme 16 32 16 32
Cetu/oxlme 1 2 2 2
Cetllbut n > 64 ,64 ;. 64 > 64
Cetpodoxlme 2 <1 <1 4
Celplo'il 0,5 05 1 4
C tClam I "> 64 64 > 64 > 64
Coldlnll 05 05 05 0.5
AdoplOd Irom [42.431
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MIC (mg/L)
p-Iactomase negative fl-Iactamose positive
50% 90% 60% 90%
Cet,x,me 0,008 0.03 0.03 0.06
Ceturoxllne 0.06 0.125 0.25 10
Cefllbulen 0.06 0.26 0.1 0.5
Celpodox,me 0,008 0.03 0.03 0.06
CelprozH 80 32 16 >64
Celelamel 0,01 0,06 0.03 0.06
Celdln" 0.008 0.03 0,01 0.06
Calocior 8.0 32 >16 >64
Adapled from [171
Table 4 The In virro aCllvllV ot Ihe nBW oral cephalosporins
agolnsl N. gonorthoeaB
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